Mark A. Velleca's Insider Trades & SAST Disclosures
Mark A. Velleca's most recent trade in Black Diamond Therapeutics Inc was a trade of 500,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 30, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Mark A. Velleca.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Black Diamond Therapeutics... | Mark A. Velleca | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics... | Mark A. Velleca | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 75,000 | 121,522 (0%) | 0% | 0 | Common Stock | |
| Black Diamond Therapeutics... | Velleca Mark A. | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 537,000 | 537,000 | - | - | Stock Option (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 08 Aug 2023 | 57,286 | 173,286 (0%) | 0% | 0.4 | 22,342 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 2.00 per share. | 08 Aug 2023 | 57,286 | 116,000 (0%) | 0% | 2.0 | 114,492 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2023 | 57,286 | 0 | - | - | Stock Option (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2023 | 2,714 | 242,286 | - | - | Stock Option (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 08 Aug 2023 | 2,714 | 118,714 (0%) | 0% | 0.3 | 814 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 2.02 per share. | 08 Aug 2023 | 2,714 | 116,000 (0%) | 0% | 2.0 | 5,482 | Common Stock |
| Black Diamond Therapeutics... | Mark A. Velleca | Director | Grant, award, or other acquisition of securities at price $ 2.10 per share. | 16 Jun 2023 | 8,929 | 41,314 (0%) | 0% | 2.1 | 18,751 | Common Stock |
| Black Diamond Therapeutics... | Mark A. Velleca | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2023 | 16,500 | 16,500 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics... | Mark A. Velleca | Director | Grant, award, or other acquisition of securities at price $ 1.67 per share. | 16 Mar 2023 | 11,228 | 32,385 (0%) | 0% | 1.7 | 18,751 | Common Stock |
| Black Diamond Therapeutics... | Mark A. Velleca | Director | Grant, award, or other acquisition of securities at price $ 1.50 per share. | 16 Dec 2022 | 8,424 | 21,157 (0%) | 0% | 1.5 | 12,636 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Oct 2022 | 15,000 | 57,286 | - | - | Stock Option (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 11.70 per share. | 18 Oct 2022 | 15,000 | 116,000 (0%) | 0% | 11.7 | 175,490 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 18 Oct 2022 | 15,000 | 131,000 (0%) | 0% | 0.4 | 5,850 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 20 Sep 2022 | 20,000 | 136,000 (0%) | 0% | 0.4 | 7,800 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2022 | 20,000 | 72,286 | - | - | Stock Option (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 13.50 per share. | 20 Sep 2022 | 20,000 | 116,000 (0%) | 0% | 13.5 | 270,044 | Common Stock |
| Black Diamond Therapeutics... | Mark A. Velleca | Director | Grant, award, or other acquisition of securities at price $ 2.62 per share. | 16 Sep 2022 | 4,294 | 12,733 (0%) | 0% | 2.6 | 11,250 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 12.64 per share. | 16 Aug 2022 | 80,000 | 116,000 (0%) | 0% | 12.6 | 1,010,904 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2022 | 80,000 | 92,286 | - | - | Stock Option (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 16 Aug 2022 | 80,000 | 196,000 (0%) | 0% | 0.4 | 31,200 | Common Stock |
| Black Diamond Therapeutics... | Mark A. Velleca | Director | Grant, award, or other acquisition of securities at price $ 2.03 per share. | 17 Jun 2022 | 5,542 | 8,439 (0%) | 0% | 2.0 | 11,250 | Common Stock |
| Black Diamond Therapeutics... | Mark A. Velleca | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics... | Mark A. Velleca | Director | Grant, award, or other acquisition of securities at price $ 3.02 per share. | 18 Mar 2022 | 2,897 | 2,897 (0%) | 0% | 3.0 | 8,749 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2022 | 15,000 | 172,286 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 07 Feb 2022 | 15,000 | 116,000 (0%) | 0% | 0.4 | 5,850 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 09 Nov 2021 | 40,000 | 101,000 (0%) | 0% | 0.4 | 15,600 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Nov 2021 | 40,000 | 187,286 | - | - | Stock Options (Right to Buy) | |
| Black Diamond Therapeutics... | Mark A. Velleca | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Aug 2021 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2021 | 10,000 | 237,286 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2021 | 10,000 | 247,286 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 18.49 per share. | 13 Jul 2021 | 10,000 | 61,000 (0%) | 0% | 18.5 | 184,898 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 13 Jul 2021 | 10,000 | 71,000 (0%) | 0% | 0.4 | 3,900 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 19.08 per share. | 13 Jul 2021 | 10,000 | 61,000 (0%) | 0% | 19.1 | 190,824 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 13 Jul 2021 | 10,000 | 71,000 (0%) | 0% | 0.4 | 3,900 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 19.45 per share. | 13 Jul 2021 | 10,000 | 61,000 (0%) | 0% | 19.5 | 194,536 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 13 Jul 2021 | 10,000 | 71,000 (0%) | 0% | 0.4 | 3,900 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2021 | 10,000 | 227,286 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 15 Jun 2021 | 10,000 | 71,000 (0%) | 0% | 0.4 | 3,900 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2021 | 10,000 | 257,286 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2021 | 10,000 | 267,286 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2021 | 10,000 | 277,286 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 21.77 per share. | 15 Jun 2021 | 10,000 | 61,000 (0%) | 0% | 21.8 | 217,728 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 15 Jun 2021 | 10,000 | 71,000 (0%) | 0% | 0.4 | 3,900 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 21.74 per share. | 15 Jun 2021 | 10,000 | 61,000 (0%) | 0% | 21.7 | 217,384 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 15 Jun 2021 | 10,000 | 71,000 (0%) | 0% | 0.4 | 3,900 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 22.39 per share. | 15 Jun 2021 | 10,000 | 61,000 (0%) | 0% | 22.4 | 223,909 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2021 | 20,000 | 287,286 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 25 May 2021 | 20,000 | 61,000 (0%) | 0% | 0.4 | 7,800 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 19.10 per share. | 11 May 2021 | 10,000 | 41,000 (0%) | 0% | 19.1 | 190,997 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2021 | 10,000 | 307,286 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2021 | 10,000 | 317,286 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2021 | 10,000 | 327,286 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 20.54 per share. | 11 May 2021 | 10,000 | 41,000 (0%) | 0% | 20.5 | 205,413 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 11 May 2021 | 10,000 | 51,000 (0%) | 0% | 0.4 | 3,900 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 20.07 per share. | 11 May 2021 | 10,000 | 41,000 (0%) | 0% | 20.1 | 200,691 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 11 May 2021 | 10,000 | 51,000 (0%) | 0% | 0.4 | 3,900 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 11 May 2021 | 10,000 | 51,000 (0%) | 0% | 0.4 | 3,900 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2021 | 10,000 | 357,286 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 13 Apr 2021 | 10,000 | 51,000 (0%) | 0% | 0.4 | 3,900 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 23.89 per share. | 13 Apr 2021 | 10,000 | 41,000 (0%) | 0% | 23.9 | 238,865 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 13 Apr 2021 | 10,000 | 51,000 (0%) | 0% | 0.4 | 3,900 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 24.53 per share. | 13 Apr 2021 | 10,000 | 41,000 (0%) | 0% | 24.5 | 245,272 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 13 Apr 2021 | 10,000 | 51,000 (0%) | 0% | 0.4 | 3,900 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 24.96 per share. | 13 Apr 2021 | 10,000 | 41,000 (0%) | 0% | 25.0 | 249,631 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2021 | 10,000 | 347,286 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2021 | 10,000 | 337,286 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.72 per share. | 16 Feb 2021 | 11,040 | 52,040 (0%) | 0% | 3.7 | 41,069 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 11,040 | 48,393 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 10,000 | 28,393 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 10,000 | 38,393 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 26.02 per share. | 16 Feb 2021 | 10,000 | 41,000 (0%) | 0% | 26.0 | 260,152 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.72 per share. | 16 Feb 2021 | 10,000 | 51,000 (0%) | 0% | 3.7 | 37,200 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.72 per share. | 16 Feb 2021 | 10,000 | 51,000 (0%) | 0% | 3.7 | 37,200 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 27.59 per share. | 16 Feb 2021 | 9,400 | 41,600 (0%) | 0% | 27.6 | 259,387 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 34.87 per share. | 16 Feb 2021 | 8,317 | 43,723 (0%) | 0% | 34.9 | 290,021 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 36.22 per share. | 16 Feb 2021 | 2,700 | 41,023 (0%) | 0% | 36.2 | 97,781 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 28.41 per share. | 16 Feb 2021 | 600 | 41,000 (0%) | 0% | 28.4 | 17,046 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 37.00 per share. | 16 Feb 2021 | 23 | 41,000 (0%) | 0% | 37 | 851 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.72 per share. | 19 Jan 2021 | 10,000 | 47,000 (0%) | 0% | 3.7 | 37,200 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2021 | 10,000 | 59,433 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2021 | 10,000 | 69,433 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2021 | 10,000 | 79,433 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 20.64 per share. | 19 Jan 2021 | 10,000 | 41,000 (0%) | 0% | 20.6 | 206,400 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.72 per share. | 19 Jan 2021 | 10,000 | 51,000 (0%) | 0% | 3.7 | 37,200 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 21.51 per share. | 19 Jan 2021 | 10,000 | 37,000 (0%) | 0% | 21.5 | 215,107 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.72 per share. | 19 Jan 2021 | 10,000 | 47,000 (0%) | 0% | 3.7 | 37,200 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Sale of securities on an exchange or to another person at price $ 20.88 per share. | 19 Jan 2021 | 10,000 | 37,000 (0%) | 0% | 20.9 | 208,781 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2021 | 4,000 | 367,286 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 19 Jan 2021 | 4,000 | 41,000 (0%) | 0% | 0.4 | 1,560 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 10,000 | 109,433 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 19.97 per share. | 15 Dec 2020 | 10,000 | 37,000 (0%) | 0% | 20.0 | 199,668 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.72 per share. | 15 Dec 2020 | 10,000 | 47,000 (0%) | 0% | 3.7 | 37,200 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 19.20 per share. | 15 Dec 2020 | 10,000 | 37,000 (0%) | 0% | 19.2 | 192,021 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.72 per share. | 15 Dec 2020 | 10,000 | 47,000 (0%) | 0% | 3.7 | 37,200 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.72 per share. | 15 Dec 2020 | 10,000 | 47,000 (0%) | 0% | 3.7 | 37,200 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 19.43 per share. | 15 Dec 2020 | 10,000 | 37,000 (0%) | 0% | 19.4 | 194,297 | Common Stock |
| G1 Therapeutics Inc | Mark A. Velleca | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 10,000 | 89,433 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Mark A. Velleca | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 10,000 | 99,433 | - | - | Stock Options (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges